Genitourinary Cancers | Specialty

Expanding the Scope of Cystoscopy: Imaging Agent Illuminates More Lesions

October 11th 2011

An interview with Neal D. Shore, MD, discussing expanding the scope of cystoscopy and the optical imaging agent Cysview.

Dr. Rini Describes Hypertension as a Biomarker

July 22nd 2011

Dr. Brian I. Rini from the Taussig Cancer Institute Describes Hypertension as a Biomarker in RCC

Dr. Rini on the Progression of Advanced RCC Therapy

July 18th 2011

Dr. Brian Rini from Taussig Cancer Institute on the Progression of Advanced RCC Therapy

Dr. Rini on Standards of Care for Advanced RCC

July 14th 2011

Dr. Brian I. Rini from the Cleveland Clinic on Standards of Care for Advanced RCC

Patients With Bladder Cancer Not Getting Recommended Care

July 14th 2011

Study results reveal that only a small fraction of patients with high-grade, noninvasive bladder cancer receive the appropriate treatment.

Dr. Rini Explains the Axitinib Integration Process

July 11th 2011

Dr. Brian I. Rini from the Taussig Cancer Institute Explains the Axitinib Integration Process

Dr. Rini on the Axitinib and Sorafenib Trial VEGF Focus

July 1st 2011

Dr. Brian Rini from Taussig Cancer Institute explains the Axitinib and Sorafenib AXIS Trial VEGF Potency Focus

Dr. Rini on the Axitinib and Sorafenib Trial Hazard Ratio

June 27th 2011

Dr. Brian Rini from the Cleveland Clinic Taussig Cancer Institute on the Axitinib and Sorafenib Trial Hazard Ratio

Dr. Rini on the Results From His Axitinib and Sorafenib Trial

June 24th 2011

Dr. Brian Rini from the Cleveland Clinic Taussig Cancer Institute on the Results From His Axitinib and Sorafenib Trial

Dr. Cella on His Focus in the Axitinib and Sorafenib Trial

June 21st 2011

Dr. David Cella from Northwestern University Feinberg School of Medicine on the Side Effect Focus of the Axitinib and Sorafenib Trial

Dr. Cella Discusses Axitinib and Sorafenib Axis Trial

June 17th 2011

Dr. Cella From Northwestern University Feinberg School of Medicine Discusses Axitinib and Sorafenib Axis Trial

Prolonged Use of Diabetes Drug Actos May Increase Risk of Bladder Cancer

June 16th 2011

The FDA announced that the prolonged use of pioglitazone (Actos) for more than 1 year has been linked to an increased risk of bladder cancer

Axitinib Outperforms Sorafenib in Renal Cell Carcinoma Trial

June 7th 2011

Axitinib demonstrated significantly better progression-free survival (PFS) compared with sorafenib

Myths and Facts About Kidney Cancer

April 12th 2011

March was National Kidney Month, so here is an opportunity to test your knowledge about kidney cancer.

March Net Guide: Kidney Cancer

April 5th 2011

Kidney cancer resource from across the web including blogs, associations, journals, clinical trials and online CME offerings

Federal Spending on Research Into Kidney Cancer Is Rising

April 4th 2011

The use of microRNAs and proteomics-based approaches for early detection are among the foremost research priorities of the National Cancer Institute

Resources for People Living with Kidney Cancer

April 4th 2011

Help kidney cancer patients by being aware of available resources and support services

Dr. Alter on Trials and Ongoing Research in Kidney Cancer

March 21st 2011

Robert S. Alter, M.D. Co-chief, Urologic Oncology, John Theurer Cancer Center, on major trials and ongoing research in kidney cancer, in the spring of 2011.

Dr. Molina on Information for the Public on Kidney Cancer

March 14th 2011

Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York, shares information that she feels the public should know about kidney cancer.

Dr. Alter on Kidney Injury in Relation to Patient Recovery

March 14th 2011